PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.
Current Team (5)Update
Funding Rounds (4) - $32.5MUpdate
Mercia Fund Management Founded in 2010 from the management buyout of WM Enterprise, Mercia Fund...
Venture capital Firm
The Capital Fund is a Â£50 million venture capital fund which backs fast-growing, small and...
The London Bioscience Innovation Centre
2 Royal College Street
London, NW1 0TU